Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009 Oct 7;2009(4):CD007611.
doi: 10.1002/14651858.CD007611.pub2.

Cryotherapy for hepatocellular carcinoma

Tahany Awad  1 , Kristian Thorlund, Christian Gluud
Affiliations

Cryotherapy for hepatocellular carcinoma

Tahany Awad et al. Cochrane Database Syst Rev. .

Abstract

Background: Hepatocellular carcinoma is the most common primary malignant cancer of the liver. Evidence for the role of cryotherapy in the treatment of hepatocellular carcinoma is controversial.

Objectives: The aim of this review is to evaluate the potential benefits and harms of cryotherapy for the treatment of hepatocellular carcinoma.

Search strategy: We searched The Cochrane Hepato-Biliary Group Controlled Trials Register, the Cochrane Central Register of Controlled Trials (CENTRAL) in The Cochrane Library, MEDLINE, EMBASE, and LILACS until June 2009. We identified further studies by searching national and topic-specific databases, bibliographies, conference abstracts, journals, and grey literature. Furthermore, we reviewed the reference lists and contacted the principal authors of the identified studies.

Selection criteria: Randomised clinical trials (irrespective of language or publication status) comparing cryotherapy with or without co-intervention(s) to placebo, no treatment, or other control interventions were considered for the review. Due to the absence of randomised clinical trials, we searched for quasi-randomised studies as well as prospective cohort studies and retrospective cohort studies.

Data collection and analysis: Two authors independently identified and assessed studies for their fulfilment of the inclusion criteria. Dichotomous data were expressed as risk ratio (RR) with 95% confidence intervals (CI). We performed the review following the recommendations of The Cochrane Collaboration.

Main results: We were unable to identify any randomised clinical trials. We were also unable to identify quasi-randomised trials. Instead, we identified two prospective cohort studies and two retrospective cohort studies. However, only one of these studies could be included for the assessment of benefit as the study results were stratified according to both the type of hepatic malignancy (primary or secondary) and the intervention group. This retrospective study compared percutaneous cryotherapy with percutaneous radiofrequency. The remaining studies were excluded for the analyses of benefit but included for the assessment of harm. Both severe and non-severe adverse events were reported, but the true nature and extent of harm was difficult to asses.

Authors' conclusions: At present, there is no evidence to recommend or refute cryotherapy for patients with hepatocellular carcinoma. Randomised clinical trials with low-risk of bias may help in defining the role of cryotherapy in the treatment of hepatocellular carcinoma.

PubMed Disclaimer

Conflict of interest statement

None known.

Figures

1.1
1.1. Analysis
Comparison 1 Percutaneous cryotherapy versus percutaneous radiofrequency ablation, Outcome 1 All‐cause mortality.
1.2
1.2. Analysis
Comparison 1 Percutaneous cryotherapy versus percutaneous radiofrequency ablation, Outcome 2 One‐year all cause mortality.
1.3
1.3. Analysis
Comparison 1 Percutaneous cryotherapy versus percutaneous radiofrequency ablation, Outcome 3 Tumour response.
1.4
1.4. Analysis
Comparison 1 Percutaneous cryotherapy versus percutaneous radiofrequency ablation, Outcome 4 Local recurrence.
See this image and copyright information in PMC

Update of

References

References to studies included in this review

Adam 2002 {published data only}
    1. Adam R, Hagopian EJ, Linhares M, Krissat J, Savier E, Azoulay D, et al. A comparison of percutaneous cryosurgery and percutaneous radiofrequency for unresectable hepatic malignancies. Archives of Surgery 2002;137(12):1332‐9. - PubMed
Bilchik 2000 {published data only}
    1. Bilchik AJ, Wood TF, Allegra D, Tsioulias GJ, Chung M, Rose DM, et al. Cryosurgical ablation and radiofrequency ablation for unresectable hepatic malignant neoplasms: a proposed algorithm. Archives of Surgery 2000;135(6):657‐62. - PubMed
Nie 2007 {published data only}
    1. Nie ZS, Feng HS, Wen JY, Zhang XH, Han ZH, Li YQ, et al. Argon‐Helium cryoablation of primary hepatic carcinoma: A clinical study of the combined therapy. Technology in Cancer Research and Treatment 2007;6(5):478‐81.
Pearson 1999 {published data only}
    1. Pearson AS, Izzo F, Fleming RY, Ellis LM, Delrio P, Roh MS, et al. Intraoperative radiofrequency ablation or cryoablation for hepatic malignancies. The American Journal of Surgery 1999;178(6):592‐9. - PubMed

References to studies excluded from this review

Adam 1997 {published data only}
    1. Adam R, Akpinar E, Johann M, Kunstlinger F, Majno P, Bismuth H. Place of cryosurgery in the treatment of malignant liver tumors. Annals of Surgery 1997;225(1):39‐50. - PMC - PubMed
Korpan 1997 {published and unpublished data}
    1. Korpan NN. Hepatic cryosurgery for liver metastases. Long‐term follow‐up. Annals of Surgery 1997;225(2):193‐201. - PMC - PubMed

Additional references

Aguilar 1993
    1. Aguilar F, Hussain S, Cerutti P. Aflatoxin B1 induces the transversion of G‐‐>T in codon 249 of the p53 tumor suppressor gene in human hepatocytes. Proceedings of the National Academy of Sciences of the United States of America 1993;90(18):8586‐90. - PMC - PubMed
Bosch 2004
    1. Bosch FX, Ribes J, Diaz M, Clqries R. Primary liver cancer: Worldwide incidence and trends. Gastroenterology 2004;127(5):S5‐S16. - PubMed
Bradburn 2006
    1. Bradburn MJ, Deeks JJ, Berlin JA, Localio AR. Much ado about nothing: a comparison of the performance of meta‐analytical methods with rare events. Statistics in Medicine 2006;26(1):53‐77. - PubMed
Brok 2008
    1. Brok J, Thorlund K, Gluud C, Wetterslev J. Trial sequential analysis reveals insufficient information size and potentially false positive results in many meta‐analyses. Journal of Clinical Epidemiology 2008;61(8):763‐9. - PubMed
Bruix 2005
    1. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology 2005; Vol. 42, issue 5:1208‐36. - PubMed
Bruix 2001
    1. Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona ‐ 2000 EASL Conference. Journal of Hepatology 2001;35:421‐30. - PubMed
Cuschieri 1995
    1. Cuschieri A, Crosthwaite G, Shimi S, Pietrabissa A, Joypaul V, Tair I, et al. Hepatic cryotherapy for liver tumors. Development and clinical evaluation of a high‐efficiency insulated multineedle probe system for open and laparoscopic use. Surgical Endoscopy 1995;9(5):483‐9. - PubMed
DeMets 1987
    1. DeMets DL. Methods of combining randomized clinical trials: strengths and limitations. Statistics in Medicine 1987;6(3):341‐50. - PubMed
DerSimonian 1986
    1. DerSimonian R, Laird N. Meta‐analysis in clinical trials. Controlled Clinical Trials 1986;7(3):177‐88. - PubMed
Deuffic 1998
    1. Deuffic S, Poynard T, Buffat L, Valleron AJ. Trends in primary liver cancer. The Lancet 1998;351(9097):214‐5. - PubMed
Egger 1997
    1. Egger M, Smith GD, Schneider M, Minder C. Bias in meta‐analysis detected by a simple, graphical test. BMJ (Clinical Research Ed.) 1997;315(7109):629‐34. - PMC - PubMed
El‐Serag 2003
    1. El‐Serag HB, Davila JA, Petersen NJ, McGlynn KA. The continuing increase in the Incidence of hepatocellular carcinoma in the United States: An update. Annals of Internal Medicine 2003;139(10):817‐23. - PubMed
Fattovich 2004
    1. Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 2004;127(5 Suppl 1):S35‐S50. - PubMed
Gluud 2009
    1. Gluud C, Nikolova D, Klingenberg SL, Whitfield K, Alexakis N, Als‐Nielsen B, et al. Cochrane Hepato‐Biliary Group. About The Cochrane Collaboration (Cochrane Review Groups (CRGs)). 2009, Issue 3. Art. No.: LIVER.
Higgins 2002
    1. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta‐analysis. Statistics in Medicine 2002;21(11):1539‐58. - PubMed
Higgins 2008
    1. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.0 [updated February 2008]. The Cochrane Colloboration, 2008. Available from www.cochrane‐handbook.org.
ICH‐GCP 1997
    1. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH harmonised tripartite guideline. Guideline for good clinical practice, CFR & ICH Guideline. PA 19063‐2043. 1997.
Ji‐Ze 2007
    1. Ji‐Ze S, Mei‐Yu G, Rong L. Clinical application of CT‐guided percutaneous targeted argon‐helium cryoablation for advanced HCC. Technology in Cancer Research and Treatment. 2007; Vol. 6:556‐60.
Kjaergard 2001
    1. Kjaergard LL, Villumsen J, Gluud C. Reported methodological quality and discrepancies between small and large randomized trials in meta‐analyses. Annals of Internal Medicine 2001;135(11):982‐9. - PubMed
Kohli 1998
    1. Kohli V, Clavien PA. Cryoablation of liver tumors. British Journal of Surgery 1998;85:1171‐2. - PubMed
Kumar 2007
    1. Kumar M, Kumar R, Hissar SS, Saraswat MK, Sharma BC, Sakhuja P, et al. Risk factors analysis for hepatocellular carcinoma in patients with and without cirrhosis: a case‐control study of 213 hepatocellular carcinoma patients from India. Journal of Gastroenterology and Hepatology 2007;22(7):1104‐11. - PubMed
Lam 1998
    1. Lam CM, Yuen WK, Fan ST. Hepatic cryosurgery for recurrent hepatocellular carcinoma after hepatectomy: a preliminary report. Journal of Surgical Oncology 1998;68(2):104‐6. - PubMed
Llovet 2003
    1. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. The Lancet 2003;362(9399):1907‐17. - PubMed
Miller 1981
    1. Miller AB, Hoogstraten B, Straquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981;47:207‐14. - PubMed
Moher 1998
    1. Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher M, et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta‐analyses?. The Lancet 1998;352:609‐13. - PubMed
Oliveri 2009
    1. Oliveri RS, Wetterslev J, Gluud C. Transarterial (chemo)embolisation for unresectable hepatocellular carcinoma. Cochrane Database of Systematic Reviews. Submitted to the Cochrane Hepato‐Biliary Group (CHBG). - PMC - PubMed
Parkin 2005
    1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA: A Cancer Journal for Clinicians 2005;55(2):74‐108. - PubMed
Regan 1989
    1. Regan LS. Screening for hepatocellular carcinoma in high‐risk individuals: A clinical review. Archives of Internal Medicine 1989;149(8):1741‐4. - PubMed
Royle 2003
    1. Royle P, Milne R. Literature searching for randomized controlled trials used in Cochrane reviews: rapid versus exhaustive searches. International Journal of Technology Assessment in Health Care 2003;19(4):591‐603. - PubMed
Rücker 2008
    1. Rücker G, Schwarzer G, Carpenter J. Arcsine test for publication bias in meta‐analyses with binary outcomes. Statistics in Medicine 2008;27:746‐63. - PubMed
Schulz 1995
    1. Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995;273(5):408‐12. - PubMed
Schwartz 2007
    1. Schwartz M, Roayaie S, Konstadoulakis M. Strategies for the management of hepatocellular carcinoma. Nature Clinical Practice Oncology 2007;4:424‐32. - PubMed
Seifert 1999
    1. Seifert JK, Morris DL. World Survey on the complications of hepatic and prostate cryotherapy. World Journal of Surgery 1999;23:109‐14. - PubMed
Shafir 1996
    1. Shafir M, Shapiro R, Sung M, Warner R, Sicular A, Klipfel A. Cryoablation of unresectable malignant liver tumors. American Journal of Surgery 1996;171:27‐31. - PubMed
Stroffolini 1998
    1. Stroffolini T, Andreone P, Andriulli A, Ascione A, Craxi A, Chiaramonte M, et al. Characteristics of hepatocellular carcinoma in Italy. Journal of Hepatology 1998;29(6):944‐52. - PubMed
Taylor‐Robinson 1997
    1. Taylor‐Robinson SD, Foster GR, Arora S, Hargreaves S, Thomas HC. Increase in primary liver cancer in the UK, 1979‐94. The Lancet 1997;350(9085):1142‐3. - PubMed
Tiribelli 1989
    1. Tiribelli C, Melato M, Croce LS, Giarelli L, Okuda K, Ohnishi K. Prevalence of hepatocellular carcinoma and relation to cirrhosis: comparison of two different cities of the world ‐ Trieste, Italy, and Chiba, Japan. Hepatology 1989;10(6):998‐1002. - PubMed
Wetterslev 2008
    1. Wetterslev J, Thorlund K, Brok J, Gluud C. Trial sequential analysis may establish when firm evidence is reached in cumulative meta‐analysis. Journal of Clinical Epidemiology 2008;61(1):64‐75. - PubMed
Wong 1998
    1. Wong WS, Patel SC, Cruz FS, Gala KV, Turner AF. Cryosurgery as a treatment for advanced stage hepatocellular carcinoma: results, complications, and alcohol ablation. Cancer 1998;82(7):1268‐78. - PubMed
Wood 2008
    1. Wood L, Egger M, Gluud LL, Schulz KF, Jüni P, Altman GD, et al. Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta‐epidemiological study. BMJ (Clinical Research Ed.) 2008;336:601‐5. - PMC - PubMed
Yeh 1989
    1. Yeh F, Yu M, Mo C, Luo S, Tong M, Henderson B. Hepatitis B virus, aflatoxins, and hepatocellular carcinoma in southern Guangxi, China. Cancer Research 1989;49:2506‐9. - PubMed
Zhou 1998
    1. Zhou XD, Tang ZY. Cryosurgery for primary liver cancer. Seminars in Surgical Oncology 1998;14(2):171‐4. - PubMed

Publication types

LinkOut - more resources